Thursday, September 29, 2016

Itraderm




Itraderm may be available in the countries listed below.


Ingredient matches for Itraderm



Itraconazole

Itraconazole is reported as an ingredient of Itraderm in the following countries:


  • Germany

  • Switzerland

International Drug Name Search

Imunomax-gamma




Imunomax-gamma may be available in the countries listed below.


Ingredient matches for Imunomax-gamma



Interferon gamma

Interferon gamma Interferon gamma-1a (a derivative of Interferon gamma) is reported as an ingredient of Imunomax-gamma in the following countries:


  • Japan

International Drug Name Search

Clozapin dura




Clozapin dura may be available in the countries listed below.


Ingredient matches for Clozapin dura



Clozapine

Clozapine is reported as an ingredient of Clozapin dura in the following countries:


  • Germany

International Drug Name Search

Wednesday, September 28, 2016

Mercaptyl




Mercaptyl may be available in the countries listed below.


Ingredient matches for Mercaptyl



Penicillamine

Penicillamine is reported as an ingredient of Mercaptyl in the following countries:


  • Switzerland

International Drug Name Search

Cortisporin Ophthalmic


Generic Name: neomycin, polymyxin b, and hydrocortisone (Ophthalmic route)


nee-oh-MYE-sin SUL-fate, pol-ee-MIX-in B SUL-fate, hye-droe-KOR-ti-sone


Commonly used brand name(s)

In the U.S.


  • Cortisporin

Available Dosage Forms:


  • Suspension

Therapeutic Class: Aminoglycoside/Corticosteroid Combination


Pharmacologic Class: Adrenal Glucocorticoid


Chemical Class: Neomycin


Uses For Cortisporin


Neomycin, polymyxin B, and hydrocortisone is a combination antibiotic and cortisone-like medicine. It is used to treat infections of the eye and to help provide relief from redness, irritation, and discomfort of certain eye problems. It is also used to help prevent permanent damage of certain eye problems.


Neomycin, polymyxin B, and hydrocortisone combination is available only with your doctor's prescription.


Before Using Cortisporin


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Studies on this medicine have been done only in adult patients, and there is no specific information comparing use in children with use in other age groups.


Geriatric


Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of ophthalmic neomycin, polymyxin B, and hydrocortisone combination in the elderly with use in other age groups.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Rotavirus Vaccine, Live

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Alcuronium

  • Aldesleukin

  • Atracurium

  • Bupropion

  • Cidofovir

  • Cisatracurium

  • Colistimethate Sodium

  • Decamethonium

  • Doxacurium

  • Ethacrynic Acid

  • Fazadinium

  • Furosemide

  • Gallamine

  • Hexafluorenium

  • Metocurine

  • Mivacurium

  • Pancuronium

  • Pipecuronium

  • Quetiapine

  • Rapacuronium

  • Rocuronium

  • Sorafenib

  • Tacrolimus

  • Tubocurarine

  • Vecuronium

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Alatrofloxacin

  • Alcuronium

  • Atracurium

  • Balofloxacin

  • Bumetanide

  • Cinoxacin

  • Ciprofloxacin

  • Cisatracurium

  • Clinafloxacin

  • Colestipol

  • Doxacurium

  • Enoxacin

  • Fazadinium

  • Fleroxacin

  • Flumequine

  • Gallamine

  • Gemifloxacin

  • Grepafloxacin

  • Hexafluorenium

  • Itraconazole

  • Levofloxacin

  • Licorice

  • Lomefloxacin

  • Metocurine

  • Mivacurium

  • Moxifloxacin

  • Norfloxacin

  • Ofloxacin

  • Pancuronium

  • Pefloxacin

  • Pipecuronium

  • Primidone

  • Prulifloxacin

  • Rapacuronium

  • Rifapentine

  • Rocuronium

  • Rosoxacin

  • Rufloxacin

  • Saiboku-To

  • Sparfloxacin

  • Temafloxacin

  • Tosufloxacin

  • Trovafloxacin Mesylate

  • Tubocurarine

  • Vecuronium

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Any other eye infection or condition or

  • Glaucoma—Use of neomycin, polymyxin B, and hydrocortisone ophthalmic drops may make the condition worse

  • Cataract surgery, recent—Use of neomycin, polymyxin B, and hydrocortisone ophthalmic drops may delay healing or cause other problems

Proper Use of Cortisporin


The bottle is only partially full to provide proper drop control.


To use:


  • First, wash your hands. Then tilt the head back and pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close the eyes. Do not blink. Keep the eyes closed for 1 or 2 minutes to allow the medicine to come into contact with the infection.

  • If you think you did not get the drop of medicine into your eye properly, use another drop.

  • To keep the medicine as germ-free as possible, do not touch the applicator tip to any surface (including the eye). Also, keep the container tightly closed.

To help clear up your infection completely, keep using this medicine for the full time of treatment, even if your symptoms have disappeared. Do not miss any doses.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For eye infection:
    • For ophthalmic suspension dosage forms:
      • Adults—One or two drops every three or four hours.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using Cortisporin


If you will be using this medicine for more than 10 days, your doctor should check your eyes at regular visits.


If your symptoms do not improve within a few days, or if they become worse, check with your doctor.


If a rash or allergic reaction develops, you should check with your doctor right away.


You should not let anyone else use your medicine. It could cause infection to spread.


Do not use any leftover medicine for future eye problems without checking with your doctor first. This medicine should not be used on many different kinds of infection.


Cortisporin Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Stop taking this medicine and get emergency help immediately if any of the following effects occur:


Rare
  • Fainting

  • lightheadedness (sudden and severe)

  • shortness of breath or trouble breathing (severe)

  • swelling around face

Check with your doctor immediately if any of the following side effects occur:


More common
  • Itching, rash, redness, swelling, or other sign of irritation not present before use of this medicine

Rare
  • Blurred vision or other change in vision

  • delayed healing of eye infection

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


Less common
  • Burning or stinging when applying medicine

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Cortisporin Ophthalmic resources


  • Cortisporin Ophthalmic Use in Pregnancy & Breastfeeding
  • Cortisporin Ophthalmic Drug Interactions
  • Cortisporin Ophthalmic Support Group
  • 0 Reviews for Cortisporin Ophthalmic - Add your own review/rating


  • Cortisporin Ophthalmic Concise Consumer Information (Cerner Multum)

  • AK-Spore HC Concise Consumer Information (Cerner Multum)

  • Ocu-Cort Concise Consumer Information (Cerner Multum)



Compare Cortisporin Ophthalmic with other medications


  • Blepharitis
  • Conjunctivitis, Bacterial
  • Keratitis
  • Keratoconjunctivitis
  • Uveitis

Medi-Lyte


Pronunciation: e-LECK-troe-lite
Generic Name: Electrolyte
Brand Name: Examples include Medi-Lyte and Temp Tabs


Medi-Lyte is used for:

Decreasing fatigue, muscle cramps, or heat exhaustion due to excessive sweating. The use of Medi-Lyte for these conditions has not been evaluated or approved by the Food and Drug Administration. It may also be used for other conditions as determined by your doctor.


Medi-Lyte is an electrolyte combination. It works by replacing electrolytes in the body.


Do NOT use Medi-Lyte if:


  • you are allergic to any ingredient in Medi-Lyte

  • you have high blood potassium levels

Contact your doctor or health care provider right away if any of these apply to you.



Before using Medi-Lyte:


Some medical conditions may interact with Medi-Lyte. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have heart disease, high blood pressure, fluid retention (eg, swelling of the hands, ankles, or feet), intestinal holes or punctures, difficulty urinating, kidney problems, or unexplained rectal bleeding

  • if you have severe or persistent vomiting or severe diarrhea, or you are dehydrated

  • if you have high levels of sodium in the blood

  • if you are unable to properly absorb glucose from food

Some MEDICINES MAY INTERACT with Medi-Lyte. However, no specific interactions with Medi-Lyte are known at this time.


Ask your health care provider if Medi-Lyte may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Medi-Lyte:


Use Medi-Lyte as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Medi-Lyte with a full glass of water (8 oz/240 mL).

  • If you miss a dose of Medi-Lyte, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Medi-Lyte.



Important safety information:


  • If vomiting, fever, or stomach pain or bloating occurs, or if you have diarrhea that continues for longer than 24 hours, check with your doctor.

  • Medi-Lyte should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Medi-Lyte while you are pregnant. It is not known if Medi-Lyte is found in breast milk. If you are or will be breast-feeding while you use Medi-Lyte, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Medi-Lyte:


All medicines may cause side effects, but many people have no, or minor, side effects. When used in small doses, no COMMON side effects have been reported with this product. Seek medical attention right away if any of these SEVERE side effects occur:



Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Medi-Lyte side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Medi-Lyte:

Store Medi-Lyte at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Keep Medi-Lyte out of the reach of children and away from pets.


General information:


  • If you have any questions about Medi-Lyte, please talk with your doctor, pharmacist, or other health care provider.

  • Medi-Lyte is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Medi-Lyte. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Medi-Lyte resources


  • Medi-Lyte Side Effects (in more detail)
  • Medi-Lyte Support Group
  • 0 Reviews · Be the first to review/rate this drug

Fleet Sof-Lax




Ingredient matches for Fleet Sof-Lax



Docusate

Docusate Sodium is reported as an ingredient of Fleet Sof-Lax in the following countries:


  • United States

International Drug Name Search

Destrometorfano Bromidrato Nova Argentia




Destrometorfano Bromidrato Nova Argentia may be available in the countries listed below.


Ingredient matches for Destrometorfano Bromidrato Nova Argentia



Dextromethorphan

Dextromethorphan hydrobromide (a derivative of Dextromethorphan) is reported as an ingredient of Destrometorfano Bromidrato Nova Argentia in the following countries:


  • Italy

International Drug Name Search

Bromhist-NR


Generic Name: brompheniramine and pseudoephedrine (BROM fen EER a meen and SOO doe ed FED rin)

Brand Names: Andehist NR Syrup, Bidhist-D, Bromaline, Bromhist Pediatric Drops, Bromhist-NR, BroveX PD, BroveX PSE, Brovex SR, Di-Bromm, Histex SR, J-TanD PD, Lodrane 12D, Lodrane 24D, Lodrane D, Lodrane Liquid, LoHist-12D, LoHist-PD, Q-Tapp, Sildec, Touro Allergy, Ultrabrom, Ultrabrom PD


What is Bromhist-NR (brompheniramine and pseudoephedrine)?

Brompheniramine is an antihistamine that reduces the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.


Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).


The combination of brompheniramine and pseudoephedrine is used to treat sneezing, cough, runny or stuffy nose, itchy or watery eyes, hives, skin rash, itching, and other symptoms of allergies and the common cold.


Brompheniramine and pseudoephedrine may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about Bromhist-NR (brompheniramine and pseudoephedrine)?


There are many brands and forms of this medicine available and not all brands are listed on this leaflet.


Do not give this medication to a child younger than 2 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Do not use any other over-the-counter cold, allergy, or sleep medication without first asking your doctor or pharmacist. If you take certain products together you may accidentally take too much of a certain drug. Read the label of any other medicine you are using to see if it contains an antihistamine or decongestant. Do not use a cough or cold medicine if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious, life-threatening side effects can occur if you take cough or cold medicine before the MAO inhibitor has cleared from your body. Brompheniramine and pseudoephedrine can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert. Avoid drinking alcohol. It can increase some of the side effects of this medication.

What should I discuss with my healthcare provider before taking Bromhist-NR (brompheniramine and pseudoephedrine)?


Do not use a cough or cold medicine if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious, life-threatening side effects can occur if you take cough or cold medicine before the MAO inhibitor has cleared from your body.

Ask a doctor or pharmacist if it is safe for you to take brompheniramine and pseudoephedrine if you have:


  • kidney disease;


  • diabetes;




  • glaucoma;




  • heart disease or high blood pressure;




  • diabetes;




  • a thyroid disorder;




  • an enlarged prostate; or




  • problems with urination.




This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Brompheniramine and pseudoephedrine can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

Artificially-sweetened liquid forms of cold medicine may contain phenylalanine. This would be important to know if you have phenylketonuria (PKU). Check the ingredients and warnings on the medication label if you are concerned about phenylalanine.


How should I take Bromhist-NR (brompheniramine and pseudoephedrine)?


Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts, or use it for longer than recommended. Cold medicine is usually taken only for a short time until your symptoms clear up.


Do not give this medication to a child younger than 2 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Take this medicine with a full glass of water. Do not crush, chew, or break an extended-release tablet. Swallow the pill whole. It is specially made to release medicine slowly in the body. Breaking or opening the pill would cause too much of the drug to be released at one time.

Measure the liquid form of this medicine with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache, cough, or skin rash.

If you need to have any type of surgery, tell the surgeon ahead of time if you have taken a cold medicine within the past few days.


This medication can cause you to have unusual results with allergy skin tests. Tell any doctor who treats you that you are taking an antihistamine.


Store the medication at room temperature away from moisture and heat.

What happens if I miss a dose?


Since cold or allergy medicine is usually taken only as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at your next regularly scheduled time. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine.

Overdose symptoms may include feeling restless or nervous, nausea, vomiting, stomach pain, dizziness, drowsiness, dry mouth, warmth or tingly feeling, or seizure (convulsions).


What should I avoid while taking Bromhist-NR (brompheniramine and pseudoephedrine)?


This medication can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert. Avoid drinking alcohol. It can increase some of the side effects of this medication.

Avoid taking diet pills, caffeine pills, or other stimulants (such as ADHD medications) without your doctor's advice. Taking a stimulant together with a decongestant can increase your risk of unpleasant side effects.


Do not use any other over-the-counter cold, allergy, or sleep medication without first asking your doctor or pharmacist. If you take certain products together you may accidentally take too much of a certain drug. Read the label of any other medicine you are using to see if it contains an antihistamine or decongestant.

Bromhist-NR (brompheniramine and pseudoephedrine) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have any of these serious side effects:

  • fast, pounding, or uneven heartbeat;




  • confusion, hallucinations, unusual thoughts or behavior;




  • severe dizziness, anxiety, restless feeling, or nervousness;




  • increased blood pressure (severe headache, blurred vision, trouble concentrating, chest pain, numbness, seizure);




  • confusion, hallucinations, unusual thoughts or behavior;




  • easy bruising or bleeding, unusual weakness, fever, chills, body aches, flu symptoms; or




  • urinating less than usual or not at all.



Less serious side effects may include:



  • blurred vision;




  • dry mouth;




  • nausea, stomach pain, constipation;




  • mild loss of appetite, stomach upset;




  • warmth, tingling, or redness under your skin;




  • sleep problems (insomnia);




  • restless or excitability (especially in children);




  • skin rash or itching;




  • dizziness, drowsiness;




  • problems with memory or concentration; or




  • ringing in your ears.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Bromhist-NR (brompheniramine and pseudoephedrine)?


Sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression or anxiety can add to sleepiness caused by brompheniramine. Tell your doctor if you regularly use any of these medicines, or any other cold or allergy medications..

Tell your doctor about all other medications you use, especially:



  • medicines to treat high blood pressure;




  • a diuretic (water pill);




  • medication to treat irritable bowel syndrome;




  • bladder or urinary medications such as oxybutynin (Ditropan, Oxytrol) or tolterodine (Detrol);




  • aspirin or salicylates (such as Disalcid, Doan's Pills, Dolobid, Salflex, Tricosal, and others);




  • a beta-blocker such as atenolol (Tenormin), carteolol (Cartrol), metoprolol (Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal), sotalol (Betapace), timolol (Blocadren), and others; or




  • antidepressants such as amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Janimine, Tofranil), and others.



This list is not complete and there may be other drugs that can interact with brompheniramine and pseudoephedrine. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.



More Bromhist-NR resources


  • Bromhist-NR Side Effects (in more detail)
  • Bromhist-NR Use in Pregnancy & Breastfeeding
  • Bromhist-NR Drug Interactions
  • Bromhist-NR Support Group
  • 0 Reviews for Bromhist-NR - Add your own review/rating


  • Bidhist-D Sustained-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Bromfenex Controlled-Release and Sustained-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)

  • Lodrane D MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Bromhist-NR with other medications


  • Hay Fever
  • Nasal Congestion


Where can I get more information?


  • Your pharmacist can provide more information about brompheniramine and pseudoephedrine.

See also: Bromhist-NR side effects (in more detail)


Anaroxyl




Anaroxyl may be available in the countries listed below.


Ingredient matches for Anaroxyl



Carbazochrome

Carbazochrome is reported as an ingredient of Anaroxyl in the following countries:


  • Bangladesh

International Drug Name Search

Tuesday, September 27, 2016

Jantoven




In the US, Jantoven (warfarin systemic) is a member of the drug class coumarins and indandiones and is used to treat Antiphospholipid Syndrome, Chronic Central Venous Catheterization, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis - First Event, Deep Vein Thrombosis - Recurrent Event, Heart Attack, Heart Failure, Prevention of Thromboembolism in Atrial Fibrillation, Prosthetic Heart Valves, Prosthetic Heart Valves - Mechanical Valves, Prosthetic Heart Valves - Tissue Valves, Protein S Deficiency, Pulmonary Embolism - First Event, Pulmonary Embolism - Recurrent Event and Thromboembolic Stroke Prophylaxis.

US matches:

  • Jantoven

Ingredient matches for Jantoven



Warfarin

Warfarin sodium salt (a derivative of Warfarin) is reported as an ingredient of Jantoven in the following countries:


  • United States

International Drug Name Search

Itraconazolo EG




Itraconazolo EG may be available in the countries listed below.


Ingredient matches for Itraconazolo EG



Itraconazole

Itraconazole is reported as an ingredient of Itraconazolo EG in the following countries:


  • Italy

International Drug Name Search

Cefamar




Cefamar may be available in the countries listed below.


Ingredient matches for Cefamar



Cefadroxil

Cefadroxil is reported as an ingredient of Cefamar in the following countries:


  • Argentina

Cefuroxime

Cefuroxime sodium salt (a derivative of Cefuroxime) is reported as an ingredient of Cefamar in the following countries:


  • Thailand

International Drug Name Search

Monday, September 26, 2016

Isodol




Isodol may be available in the countries listed below.


Ingredient matches for Isodol



Nimesulide

Nimesulide is reported as an ingredient of Isodol in the following countries:


  • Italy

International Drug Name Search

Lomudal




Lomudal may be available in the countries listed below.


Ingredient matches for Lomudal



Cromoglicic Acid

Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Lomudal in the following countries:


  • Belgium

  • Denmark

  • Finland

  • France

  • Greece

  • Iceland

  • Israel

  • Italy

  • Luxembourg

  • Netherlands

  • Norway

  • Sweden

  • Switzerland

International Drug Name Search

Fudosteine




Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0013189-98-5

Chemical Formula

C6-H13-N-O3-S

Molecular Weight

179

Therapeutic Category

Expectorant

Chemical Names

(-)-R-2-Amino-3-(3-hydroxypropylthio)propionic acid (JAN)

(-)-3-[(3-Hydroxypropyl)thiol]-L-alanine (WHO)

L-Cysteine, S-(3-hydroxypropyl)-

Foreign Names

  • Fudosteinum (Latin)
  • Fudostein (German)
  • Fudostéine (French)
  • Fudosteina (Spanish)

Generic Names

  • Fudosteine (OS: JAN)
  • SS-320A (IS)
  • UNII-UR9VPI71PT (IS)

Brand Names

  • Cleanal
    Tanabe Mitsubishi, Japan


  • Spelear
    Hisamitsu, Japan

International Drug Name Search

Glossary

ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Isodine




Isodine may be available in the countries listed below.


Ingredient matches for Isodine



Povidone Iodine

Povidone-Iodine is reported as an ingredient of Isodine in the following countries:


  • Colombia

  • Indonesia

  • Japan

  • Mexico

  • Peru

  • Thailand

International Drug Name Search

Baklofen Mylan




Baklofen Mylan may be available in the countries listed below.


Ingredient matches for Baklofen Mylan



Baclofen

Baclofen is reported as an ingredient of Baklofen Mylan in the following countries:


  • Sweden

International Drug Name Search

Itorelin




Itorelin may be available in the countries listed below.


Ingredient matches for Itorelin



Buserelin

Buserelin acetate (a derivative of Buserelin) is reported as an ingredient of Itorelin in the following countries:


  • Japan

International Drug Name Search

Friday, September 23, 2016

Indast




Indast may be available in the countries listed below.


Ingredient matches for Indast



Cilastatin

Cilastatin sodium salt (a derivative of Cilastatin) is reported as an ingredient of Indast in the following countries:


  • Japan

Imipenem

Imipenem monohydrate (a derivative of Imipenem) is reported as an ingredient of Indast in the following countries:


  • Japan

International Drug Name Search

liotrix


lee-voe-thye-ROX-een SOE-dee-um, lye-oh-THYE-roe-neen SOE-dee-um


Commonly used brand name(s)

In the U.S.


  • Euthroid

  • Thyrolar

Available Dosage Forms:


  • Tablet

Therapeutic Class: Thyroid Supplement


Uses For liotrix


Liotrix is used to treat hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone. It is also used to help decrease the size of enlarged thyroid glands (known as goiter) and to treat thyroid cancer .


Liotrix is also used in some medical tests to help diagnose problems with the thyroid gland .


liotrix is available only with your doctor's prescription .


Before Using liotrix


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For liotrix, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to liotrix or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies performed to date have not demonstrated pediatrics-specific problems that would limit the usefulness of liotrix in children .


Geriatric


Appropriate studies performed to date have not demonstrated geriatrics-specific problems that would limit the usefulness of liotrix in the elderly. However, elderly patients are more likely to have age-related heart and blood vessel problems, which may require caution in patients receiving liotrix .


Pregnancy








Pregnancy CategoryExplanation
All TrimestersAAdequate studies in pregnant women have not shown an increased risk of fetal abnormalities.

Breast Feeding


Levothyroxine

Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.


Liothyronine

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking liotrix, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using liotrix with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Acenocoumarol

  • Aluminum Carbonate, Basic

  • Aluminum Hydroxide

  • Aluminum Phosphate

  • Anisindione

  • Calcium Acetate

  • Calcium Carbonate

  • Calcium Citrate

  • Cholestyramine

  • Chromium

  • Colesevelam

  • Conjugated Estrogens

  • Dicumarol

  • Dihydroxyaluminum Aminoacetate

  • Dihydroxyaluminum Sodium Carbonate

  • Eltrombopag

  • Esterified Estrogens

  • Estradiol

  • Estriol

  • Estrone

  • Estropipate

  • Imatinib

  • Iron

  • Kelp

  • Lanthanum Carbonate

  • Lopinavir

  • Magaldrate

  • Magnesium Carbonate

  • Magnesium Hydroxide

  • Magnesium Oxide

  • Magnesium Trisilicate

  • Phenindione

  • Phenprocoumon

  • Phenytoin

  • Rifampin

  • Rifapentine

  • Ritonavir

  • Sevelamer

  • Simvastatin

  • Sodium Polystyrene Sulfonate

  • Soybean

  • Warfarin

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using liotrix with any of the following may cause an increased risk of certain side effects but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use liotrix, or give you special instructions about the use of food, alcohol, or tobacco.


  • Enteral Nutrition

Other Medical Problems


The presence of other medical problems may affect the use of liotrix. Make sure you tell your doctor if you have any other medical problems, especially:


  • Adrenal insufficiency (untreated) or

  • Thyrotoxicosis (untreated, overactive thyroid)—liotrix should NOT be used in patients with any of these conditions .

  • Clotting disorder or

  • Diabetes or

  • Heart disease (history of) or

  • Other adrenal gland problems—Use with caution. Dosage adjustment may be needed .

Proper Use of liotrix


liotrix usually needs to be taken for the rest of your life. Do not stop taking liotrix or change your doses without first checking with your doctor. It may take several weeks before you start to notice an improvement in your symptoms .


Dosing


The dose of liotrix will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of liotrix. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For oral dosage form (tablet):
    • For the treatment of hypothyroidism:
      • Adults—At first, one tablet of liotrix (Thyrolar-1/2) containing 6.25 microgram (mcg) of liothyronine and 25 mcg of levothyroxine once a day. Your doctor may increase your dose by one tablet of liotrix (Thyrolar-1/4) containing 3.1 mcg of liothyronine and 12.5 mcg of levothyroxine every 2 to 3 weeks. However, the dose is usually not more than one tablet of liotrix (Thyrolar-3) containing 37.5 mcg of liothyronine and 150 mcg of levothyroxine once a day.

      • Children—Follow dosing for the treatment of congenital hypothyroidism .


    • For the treatment of congenital hypothyroidism:
      • Children 0 to 6 months of age—At first, 3.1 mcg of liothyronine and 12.5 mcg of levothyroxine once a day. Doses may be increased as needed. However, the dose is usually not more than 6.25 mcg of liothyronine and 25 mcg of levothyroxine once a day.

      • Children 6 to 12 months of age—At first, 6.25 mcg of liothyronine and 25 mcg of levothyroxine once a day. Doses may be increased as needed. However, the dose is usually not more than 9.35 mcg of liothyronine and 37.5 mcg of levothyroxine once a day.

      • Children 1 to 5 years of age—At first, 9.35 mcg of liothyronine and 37.5 mcg of levothyroxine once a day. Doses may be increased as needed. However, the dose is usually not more than 12.5 mcg of liothyronine and 50 mcg of levothyroxine once a day.

      • Children 6 to 12 years of age—At first, 12.5 mcg of liothyronine and 50 mcg of levothyroxine once a day. Doses may be increased as needed. However, the dose is usually not more than 18.75 mcg of liothyronine and 75 mcg of levothyroxine once a day.

      • Children over 12 years of age—The usual dose is 18.75 mcg of liothyronine and 75 mcg of levothyroxine once a day. Doses may be increased as needed .



Missed Dose


If you miss a dose of liotrix, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Store in the refrigerator. Do not freeze.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using liotrix


It is very important that your doctor check your progress at regular visits. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to take it. Blood and urine tests will be needed to check for unwanted effects .


Liotrix should not be used for the treatment of obesity or for the purpose of losing weight. liotrix is ineffective for weight reduction and when taken in larger amount, it may cause more serious medical conditions .


Hypothyroidism can sometimes cause infertility in men and women. Liotrix should not be used for the treatment of infertility unless it is caused by hypothyroidism .


Call your doctor right away if you start to have chest pain, fast or irregular heartbeat, excessive sweating, heat intolerance, nervousness, or any other unusual medical condition .


For patients with diabetes, it is very important that you keep track of your blood or urine sugar levels as instructed by your doctor. Check with your doctor immediately if you notice any changes in your sugar levels .


A temporary loss of hair may occur during the first few months of liotrix therapy. Ask your doctor about this if you have any concerns .


liotrix Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


Incidence not determined
  • Chest pain

  • constipation

  • depressed mood

  • difficulty in moving

  • discouragement

  • dryness of the eye

  • dry skin and hair

  • fast, irregular, pounding, or racing heartbeat or pulse

  • fear, nervousness

  • feeling cold

  • feeling sad or empty

  • fever

  • headache

  • hives or welts

  • hoarseness or husky voice

  • increased sweating

  • increased weight

  • increase in blood pressure

  • irritability

  • irritation

  • itching skin

  • joint pain, stiffness or swelling

  • lack of appetite

  • lack or loss of strength

  • loss of interest or pleasure

  • muscle aching or cramping

  • muscle pain or stiffness

  • nausea

  • redness of skin

  • shakiness in legs, arms, hands, feet

  • shortness of breath

  • skin rash

  • sleeplessness

  • slowed heartbeat

  • sluggishness

  • swelling of eyelids, face, lips, hands, or feet

  • swollen joints

  • tightness in chest

  • tiredness

  • trembling or shaking of hands or feet

  • trouble concentrating

  • troubled breathing or swallowing

  • trouble sleeping

  • unable to sleep

  • unusual tiredness or weakness

  • weight gain

  • wheezing

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


Incidence not determined
  • Hair loss, thinning of hair

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: liotrix side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More liotrix resources


  • Liotrix Side Effects (in more detail)
  • Liotrix Use in Pregnancy & Breastfeeding
  • Liotrix Drug Interactions
  • Liotrix Support Group
  • 0 Reviews for Liotrix - Add your own review/rating


  • liotrix Concise Consumer Information (Cerner Multum)

  • Liotrix Professional Patient Advice (Wolters Kluwer)

  • Liotrix Monograph (AHFS DI)

  • Liotrix MedFacts Consumer Leaflet (Wolters Kluwer)



Compare liotrix with other medications


  • Underactive Thyroid

Codotussyl Expectorant




Codotussyl Expectorant may be available in the countries listed below.


Ingredient matches for Codotussyl Expectorant



Acetylcysteine

Acetylcysteine is reported as an ingredient of Codotussyl Expectorant in the following countries:


  • France

International Drug Name Search

Thursday, September 22, 2016

Diclofenackalium




Diclofenackalium may be available in the countries listed below.


Ingredient matches for Diclofenackalium



Diclofenac

Diclofenac potassium salt (a derivative of Diclofenac) is reported as an ingredient of Diclofenackalium in the following countries:


  • Netherlands

  • Norway

International Drug Name Search

Itropin




Itropin may be available in the countries listed below.


Ingredient matches for Itropin



Atropine

Atropine sulfate (a derivative of Atropine) is reported as an ingredient of Itropin in the following countries:


  • Bangladesh

International Drug Name Search

Imosec




Imosec may be available in the countries listed below.


Ingredient matches for Imosec



Loperamide

Loperamide is reported as an ingredient of Imosec in the following countries:


  • Luxembourg

Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Imosec in the following countries:


  • Brazil

International Drug Name Search

Azithromycin AbZ




Azithromycin AbZ may be available in the countries listed below.


Ingredient matches for Azithromycin AbZ



Azithromycin

Azithromycin monohydrate (a derivative of Azithromycin) is reported as an ingredient of Azithromycin AbZ in the following countries:


  • Germany

International Drug Name Search

Veregen


Veregen is a brand name of sinecatechins topical, approved by the FDA in the following formulation(s):


VEREGEN (sinecatechins - ointment; topical)



  • Manufacturer: MEDIGENE AG

    Approval date: October 31, 2006

    Strength(s): 15% [RLD]

Has a generic version of Veregen been approved?


No. There is currently no therapeutically equivalent version of Veregen available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Veregen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Composition for treating Condyloma acuminata
    Patent 5,795,911
    Issued: August 18, 1998
    Inventor(s): Cheng; Shu Jun & Wang; De Chang & Hara; Yukihiko
    Assignee(s): Cancer Institute (Hospital), Chinese Academy of Medical Sciences
    Mitsui Norin Co., Ltd.
    A composition for a treatment of HPV-infected Condyloma acuminata which comprises containing tea catechin as a main component. This medication has no danger of side-effects and may be easily applied to or inserted in the infected area by the patient themselves.
    Patent expiration dates:

    • October 31, 2020
      ✓ 
      Patent use: TREATMENT OF GENITAL WARTS




  • Method for treating hyperplasia
    Patent 5,968,973
    Issued: October 19, 1999
    Inventor(s): Cheng; Shu Jun & Wang; De Chang & Hara; Yukihiko
    Assignee(s): Cancer Institute (Hospital), Chinese Academy of Medical Sciences
    Mitsui Norin Co., Ltd.
    A method for a treatment of hyperplasia caused by papilloma virus, such as for treating Condyloma acuminata which comprises administering tea catechin. Tea catechins do not involve the risk of side-effects and may be easily applied to or inserted in the infected area by the patients themselves.
    Patent expiration dates:

    • April 10, 2017
      ✓ 
      Patent use: TREATMENT OF GENITAL WARTS




  • Medicament for the treatment of viral skin and tumour diseases
    Patent 7,858,662
    Issued: December 28, 2010
    Inventor(s): Chang; Yunik & Lathrop; Robert & Böhm; Erwin & Gander-Meisterernst; Irene & Greger; Regina & Holldack; Johanna & Moebius; Ulrich
    Assignee(s): MediGene AG
    The invention relates to a medicament containing a compound of general formula (1), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkynyl group, preferably a C11-C15 alkyl, alkylene or alkynyl group, particularly a C11-C13 alkyl, alkylene or alkynyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkynyl group, preferably a C1-C6 alkyl, alkylene or alkynyl group, in particular a C2-C4 alkyl, alkylene or alkynyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m—O]nH group with n=1 to 10, preferably n=1 to 5, m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—(R3)]— group, where R3=independent H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.
    Patent expiration dates:

    • October 2, 2026
      ✓ 
      Patent use: TREATMENT OF GENITAL WARTS
      ✓ 
      Drug product



See also...

  • Veregen Consumer Information (Drugs.com)
  • Veregen Consumer Information (Wolters Kluwer)
  • Veregen topical Consumer Information (Cerner Multum)
  • Veregen Advanced Consumer Information (Micromedex)
  • Veregen AHFS DI Monographs (ASHP)
  • Polyphenon E Consumer Information (Drugs.com)
  • Sinecatechins Consumer Information (Wolters Kluwer)
  • Kunecatechins topical Consumer Information (Cerner Multum)
  • Sinecatechins topical Consumer Information (Cerner Multum)
  • Sinecatechins Topical application Advanced Consumer Information (Micromedex)
  • Sinecatechins AHFS DI Monographs (ASHP)

Cravit Ophthalmic




Cravit Ophthalmic may be available in the countries listed below.


Ingredient matches for Cravit Ophthalmic



Levofloxacin

Levofloxacin is reported as an ingredient of Cravit Ophthalmic in the following countries:


  • Thailand

International Drug Name Search

Bendarabin




Bendarabin may be available in the countries listed below.


Ingredient matches for Bendarabin



Fludarabine

Fludarabine phosphate (a derivative of Fludarabine) is reported as an ingredient of Bendarabin in the following countries:


  • Germany

International Drug Name Search

Induxin




Induxin may be available in the countries listed below.


Ingredient matches for Induxin



Oxytocin

Oxytocin is reported as an ingredient of Induxin in the following countries:


  • Indonesia

  • Myanmar

International Drug Name Search

Wednesday, September 21, 2016

Dexol 5




Dexol 5 may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Dexol 5



Dexamethasone

Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Dexol 5 in the following countries:


  • Australia

  • New Zealand

International Drug Name Search

Beniod




Beniod may be available in the countries listed below.


Ingredient matches for Beniod



Delapril

Delapril is reported as an ingredient of Beniod in the following countries:


  • Spain

International Drug Name Search

Telaprevir


Pronunciation: tel-A-pre-vir
Generic Name: Telaprevir
Brand Name: Incivek


Telaprevir is used for:

Treating chronic hepatitis C virus infection in certain patients. It must be used in combination with peginterferon and ribavirin.


Telaprevir is a hepatitis C virus protease inhibitor. It reduces the amount of hepatitis C virus in the body by preventing the spread of the hepatitis C virus within the body.


Do NOT use Telaprevir if:


  • you are allergic to any ingredient in Telaprevir

  • you have moderate to severe liver problems

  • you are taking alfuzosin, certain benzodiazepines (eg, oral midazolam, triazolam), cabazitaxel, cisapride, conivaptan, dronedarone, ergot derivatives (eg, dihydroergotamine, ergonovine, ergotamine, methylergonovine), certain HMG-CoA reductase inhibitors (eg, atorvastatin, lovastatin, simvastatin), lurasidone, pimozide, rifabutin, rifampin, rivaroxaban, silodosin, St. John's wort, or tolvaptan

  • you are taking sildenafil or tadalafil to treat pulmonary arterial hypertension (PAH)

Contact your doctor or health care provider right away if any of these apply to you.



Before using Telaprevir:


Some medical conditions may interact with Telaprevir. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have HIV infection; other immune system problems; gout or high blood uric acid levels; or certain blood problems, such as anemia, low blood platelet levels, or low white blood cell levels (neutropenia)

  • if you have other liver problems (eg, hepatitis B infection)

  • if you have had an organ transplant

  • if you will be having surgery

Some MEDICINES MAY INTERACT with Telaprevir. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Rifabutin, rifampin, or St. John's wort because they may decrease Telaprevir's effectiveness

  • Alfuzosin, certain benzodiazepines (eg, oral midazolam, triazolam), cabazitaxel, cisapride, conivaptan, dronedarone , ergot derivatives (eg, dihydroergotamine, ergonovine, ergotamine, methylergonovine), certain HMG-CoA reductase inhibitors (eg, atorvastatin, lovastatin, simvastatin), lurasidone, pimozide, rivaroxaban, silodosin, or tolvaptan because the risk of their side effects may be increased by Telaprevir

  • Sildenafil or tadalafil (when used to treat PAH) because the risk of their side effects may be increased by Telaprevir

  • Hormonal birth control (eg, birth control pills) because their effectiveness may be decreased by Telaprevir

  • Many prescription medicines (eg, used for asthma or breathing problems, anxiety, birth control, blood thinning, blood flow, cancer, diabetes, enlarged prostate, erectile dysfunction, gout, angina, heart problems, HIV, immune suppression, infection, inflammation, irregular heartbeat, high blood pressure, high cholesterol, mental or mood problems, pain (eg, narcotics), PAH, seizures, sleep) may interact with Telaprevir, increasing the risk of side effects or decreasing effectiveness

This may not be a complete list of all interactions that may occur. Ask your health care provider if Telaprevir may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Telaprevir:


Use Telaprevir as directed by your doctor. Check the label on the medicine for exact dosing instructions. Check the label on the medicine for exact dosing instructions.


  • Telaprevir comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Telaprevir refilled.

  • Telaprevir must be taken with peginterferon and ribavirin, which come with their own Medication Guides. Be sure to read those Medication Guides each time you get them filled.

  • Take Telaprevir by mouth with food (not low fat). Eat a meal or snack that contains about 20 grams of fat within 30 minutes before you take Telaprevir. Examples of some foods include: a bagel with cream cheese, 1 cup nuts, 3 tablespoons peanut butter, 1 cup ice cream; 2 ounces American or cheddar cheese, 2 ounces potato chips, or 1 cup trail mix.

  • Telaprevir works best if it is taken at the same time each day. Each dose should be taken 7 to 9 hours apart.

  • Continue to take Telaprevir even if you feel well. Do not miss any doses.

  • If you miss a dose of Telaprevir and you remember within 4 hours of when you usually take it, take the missed dose with food as soon as possible and go back to your regular dosing schedule. If you miss a dose of Telaprevir and it is more than 4 hours after the time you usually take it, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Telaprevir.



Important safety information:


  • Mild skin rashes are common with the use of Telaprevir. Sometimes these skin rashes and other skin reactions can become severe. Contact your doctor right away if you develop a rash with or without itching; fever; mouth sores or ulcers; red or irritated eyes; red, swollen, blistered, or peeling skin; or swelling of the face.

  • Telaprevir may lower the ability of your body to fight infection. Avoid contact with people who have colds or infections. Tell your doctor if you notice signs of infection like fever, sore throat, rash, or chills.

  • Telaprevir may reduce the number of clot-forming cells (platelets) in your blood. Avoid activities that may cause bruising or injury. Tell your doctor if you have unusual bruising or bleeding. Tell your doctor if you have dark, tarry, or bloody stools.

  • Telaprevir does not stop you from spreading hepatitis C virus to others through sexual contact, sharing needles, or being exposed to your blood. Use barrier methods of birth control (eg, condoms) if you have hepatitis C virus infection. Talk with your doctor about safe sexual practices that protect your partner. Never share needles or other injection supplies. Do not share personal items that may have blood or body fluids on them, like toothbrushes or razors.

  • Do not change your dose without checking with your doctor.

  • Telaprevir is not a cure for hepatitis C virus infection. Remain under the care of your doctor.

  • When your medicine supply is low, get more from your doctor or pharmacist as soon as you can. Do not stop taking Telaprevir, even for a short period of time. If you do, the virus may grow resistant to the medicine and become harder to treat.

  • Women who may become pregnant and men who use Telaprevir must use 2 effective forms of birth control while they take Telaprevir with ribavirin and for 6 months after treatment is stopped. Hormonal birth control (eg, birth control pills) may not be as effective while you are using Telaprevir and for up to 2 weeks after stopping Telaprevir. Talk with your doctor if you have questions about effective birth control.

  • Lab tests, including complete blood cell counts, electrolyte levels, liver and kidney function, hepatitis C virus antibody levels, thyroid function, and uric acid levels, may be performed while you use Telaprevir and for several months after you stop Telaprevir. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Telaprevir with caution in the ELDERLY; they may be more sensitive to its effects.

  • Telaprevir should be used with extreme caution in CHILDREN younger than 18 years; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: Telaprevir must be used with ribavirin. Ribavirin use during pregnancy has resulted in birth defects and fetal death. If you are able to become pregnant, talk with your doctor or pharmacist about the use of effective birth control while using Telaprevir. If you become pregnant, contact your doctor immediately. You will need to discuss the benefits and risks of using Telaprevir while you are pregnant. It is not known if Telaprevir is found in breast milk. Do not breast-feed while taking Telaprevir.


Possible side effects of Telaprevir:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Anal or rectal problems (eg, burning, discomfort, itching, hemorrhoids); change in taste; diarrhea; nausea; tiredness; vomiting.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); change in the amount of urine produced; dark, tarry, or bloody stools; dizziness; fast or irregular heartbeat; feeling cold, especially in the hands or feet; fever, chills, or sore throat; joint pain (especially in the big toe); mouth sores or ulcers; pale skin; rash (with or without itching); red or irritated eyes; red, swollen, blistered, or peeling skin; severe or prolonged nausea or vomiting; shortness of breath; swelling of the face; unusual tiredness or weakness; yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Telaprevir side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms include change in taste; decreased appetite; diarrhea; headache; nausea; vomiting.


Proper storage of Telaprevir:

Store Telaprevir at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Once the bottle is opened, use within 28 days. Keep Telaprevir out of the reach of children and away from pets.


General information:


  • If you have any questions about Telaprevir, please talk with your doctor, pharmacist, or other health care provider.

  • Telaprevir is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Telaprevir. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Telaprevir resources


  • Telaprevir Side Effects (in more detail)
  • Telaprevir Use in Pregnancy & Breastfeeding
  • Telaprevir Drug Interactions
  • Telaprevir Support Group
  • 1 Review for Telaprevir - Add your own review/rating


  • Telaprevir Professional Patient Advice (Wolters Kluwer)

  • telaprevir Advanced Consumer (Micromedex) - Includes Dosage Information

  • Incivek Prescribing Information (FDA)

  • Incivek Consumer Overview



Compare Telaprevir with other medications


  • Hepatitis C

Itraconazol Merck




Itraconazol Merck may be available in the countries listed below.


Ingredient matches for Itraconazol Merck



Itraconazole

Itraconazole is reported as an ingredient of Itraconazol Merck in the following countries:


  • Netherlands

  • Spain

International Drug Name Search

Tensan retard




Tensan retard may be available in the countries listed below.


Ingredient matches for Tensan retard



Nilvadipine

Nilvadipine is reported as an ingredient of Tensan retard in the following countries:


  • Austria

International Drug Name Search

Temazepam




Dosage Form: capsule
Temazepam Capsules, USP CIV

Temazepam Description


Temazepam is a benzodiazepine hypnotic agent. The chemical name is 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one, and the structural formula is:



Temazepam is a white, crystalline substance, very slightly soluble in water and sparingly soluble in alcohol, USP.


Temazepam capsules, 15 mg and 30 mg, are for oral administration.


Active ingredient: Temazepam, USP


Inactive ingredients: corn starch, hypromellose, lactose monohydrate, magnesium stearate, and sodium lauryl sulfate. The capsule shells and imprinting inks contain: gelatin, iron oxide black, shellac, propylene glycol, titanium dioxide, methylparaben, butylparaben, propylparaben, benzyl alcohol, sodium propionate and edetate calcium disodium. The 15 mg capsules also contain D&C Yellow #10 and FD&C Blue #1.



Temazepam - Clinical Pharmacology



Pharmacokinetics


In a single and multiple dose absorption, distribution, metabolism, and excretion (ADME) study, using 3H labeled drug, Temazepam capsules were well absorbed and found to have minimal (8%) first pass metabolism. There were no active metabolites formed and the only significant metabolite present in blood was the O-conjugate. The unchanged drug was 96% bound to plasma proteins. The blood level decline of the parent drug was biphasic with the short half-life ranging from 0.4 to 0.6 hours and the terminal half-life from 3.5 to 18.4 hours (mean 8.8 hours), depending on the study population and method of determination. Metabolites were formed with a half-life of 10 hours and excreted with a half-life of approximately 2 hours. Thus, formation of the major metabolite is the rate limiting step in the biodisposition of Temazepam. There is no accumulation of metabolites. A dose-proportional relationship has been established for the area under the plasma concentration/time curve over the 15 to 30 mg dose range.


Temazepam was completely metabolized through conjugation prior to excretion; 80% to 90% of the dose appeared in the urine. The major metabolite was the O-conjugate of Temazepam (90%); the O-conjugate of N-desmethyl Temazepam was a minor metabolite (7%).



Bioavailability, Induction, and Plasma Levels


Following ingestion of a 30 mg Temazepam capsule, measurable plasma concentrations were achieved 10 to 20 minutes after dosing with peak plasma levels ranging from 666 to 982 ng/mL (mean 865 ng/mL) occurring approximately 1.2 to 1.6 hours (mean 1.5 hours) after dosing.


In a 7 day study, in which subjects were given a 30 mg Temazepam capsule 1 hour before retiring, steady-state (as measured by the attainment of maximal trough concentrations) was achieved by the third dose. Mean plasma levels of Temazepam (for days 2 to 7) were 260±210 ng/mL at 9 hours and 75±80 ng/mL at 24 hours after dosing. A slight trend toward declining 24 hour plasma levels was seen after day 4 in the study, however, the 24 hour plasma levels were quite variable.


At a dose of 30 mg once-a-day for 8 weeks, no evidence of enzyme induction was found in man.



Elimination Rate of Benzodiazepine Hypnotics and Profile of Common Untoward Effects


The type and duration of hypnotic effects and the profile of unwanted effects during administration of benzodiazepine hypnotics may be influenced by the biologic half-life of the administered drug and for some hypnotics, the half-life of any active metabolites formed. Benzodiazepine hypnotics have a spectrum of half-lives from short (<4 hours) to long (>20 hours). When half-lives are long, drug (and for some drugs their active metabolites) may accumulate during periods of nightly administration and be associated with impairments of cognitive and/or motor performance during waking hours; the possibility of interaction with other psychoactive drugs or alcohol will be enhanced. In contrast, if half-lives are shorter, drug (and, where appropriate, its active metabolites) will be cleared before the next dose is ingested and carry-over effects related to excessive sedation or CNS depression should be minimal or absent. However, during nightly use for an extended period, pharmacodynamic tolerance or adaptation to some effects of benzodiazepine hypnotics may develop. If the drug has a short elimination half-life, it is possible that a relative deficiency of the drug, or, if appropriate, its active metabolites (i.e., in relationship to the receptor site) may occur at some point in the interval between each night’s use. This sequence of events may account for 2 clinical findings reported to occur after several weeks of nightly use of rapidly eliminated benzodiazepine hypnotics, namely, increased wakefulness during the last third of the night, and the appearance of increased signs of daytime anxiety.



Controlled Trials Supporting Efficacy


Temazepam capsules improved sleep parameters in clinical studies. Residual medication effects (“hangover”) were essentially absent. Early morning awakening, a particular problem in the geriatric patient, was significantly reduced.


Patients with chronic insomnia were evaluated in 2 week, placebo controlled sleep laboratory studies with Temazepam capsules at doses of 7.5 mg, 15 mg, and 30 mg given 30 minutes prior to bedtime. There was a linear dose-response improvement in total sleep time and sleep latency, with significant drug-placebo differences at 2 weeks occurring only for total sleep time at the 2 higher doses, and for sleep latency only at the highest dose.


In these sleep laboratory studies, REM sleep was essentially unchanged and slow wave sleep was decreased. No measurable effects on daytime alertness or performance occurred following Temazepam capsules treatment or during the withdrawal period, even though a transient sleep disturbance in some sleep parameters was observed following withdrawal of the higher doses. There was no evidence of tolerance development in the sleep laboratory parameters when patients were given Temazepam capsules nightly for at least 2 weeks.


In addition, normal subjects with transient insomnia associated with first night adaptation to the sleep laboratory were evaluated in 24 hour, placebo controlled sleep laboratory studies with Temazepam capsules at doses of 7.5 mg, 15 mg, and 30 mg, given 30 minutes prior to bedtime. There was a linear dose-response improvement in total sleep time, sleep latency and number of awakenings, with significant drug-placebo differences occurring for sleep latency at all doses, for total sleep time at the 2 higher doses and for number of awakenings only at the 30 mg dose.



Indications and Usage for Temazepam


Temazepam capsules are indicated for the short-term treatment of insomnia (generally 7 to 10 days).


For patients with short-term insomnia, instructions in the prescription should indicate that Temazepam capsules should be used for short periods of time (7 to 10 days).


The clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment.



Contraindications


Benzodiazepines may cause fetal harm when administered to a pregnant woman. An increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. Transplacental distribution has resulted in neonatal CNS depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy.


Reproduction studies in animals with Temazepam were performed in rats and rabbits. In a perinatal-postnatal study in rats, oral doses of 60 mg/kg/day resulted in increasing nursling mortality. Teratology studies in rats demonstrated increased fetal resorptions at doses of 30 and 120 mg/kg in one study and increased occurrence of rudimentary ribs, which are considered skeletal variants, in a second study at doses of 240 mg/kg or higher. In rabbits, occasional abnormalities such as exencephaly and fusion or asymmetry of ribs were reported without dose relationship. Although these abnormalities were not found in the concurrent control group, they have been reported to occur randomly in historical controls. At doses of 40 mg/kg or higher, there was an increased incidence of the 13th rib variant when compared to the incidence in concurrent and historical controls.


Temazepam capsules are contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Patients should be instructed to discontinue the drug prior to becoming pregnant. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered.



Warnings


Sleep disturbance may be the presenting manifestation of an underlying physical and/or psychiatric disorder. Consequently, a decision to initiate symptomatic treatment of insomnia should only be made after the patient has been carefully evaluated. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of insomnia may be the consequence of an unrecognized psychiatric or physical disorder as may the emergence of new abnormalities of thinking or behavior. Such abnormalities have also been reported to occur in association with the use of drugs with central nervous system depressant activity, including those of the benzodiazepine class. Because some of the worrisome adverse effects of benzodiazepines, including Temazepam capsules, appear to be dose related (see PRECAUTIONS and DOSAGE AND ADMINISTRATION), it is important to use the lowest possible effective dose. Elderly patients are especially at risk.


Some of these changes may be characterized by decreased inhibition, e.g., aggressiveness and extroversion that seem out of character, similar to that seen with alcohol. Other kinds of behavioral changes can also occur, for example, bizarre behavior, agitation, hallucinations, and depersonalization. Complex behaviors such as “sleep-driving” (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with amnesia for the event) have been reported. These events can occur in sedative-hypnotic-naive as well as in sedative-hypnotic-experienced persons. Although behaviors such as sleep-driving may occur with Temazepam capsules alone at therapeutic doses, the use of alcohol and other CNS depressants with Temazepam capsules appears to increase the risk of such behaviors, as does the use of Temazepam capsules at doses exceeding the maximum recommended dose. Due to the risk to the patient and the community, discontinuation of Temazepam capsules should be strongly considered for patients who report a “sleep-driving” episode. Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with sleep-driving, patients usually do not remember these events. Amnesia and other neuro-psychiatric symptoms may occur unpredictably. In primarily depressed patients, worsening of depression, including suicidal thinking has been reported in association with the use of sedative/hypnotics.


It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.


Withdrawal symptoms (of the barbiturate type) have occurred after the abrupt discontinuation of benzodiazepines (see DRUG ABUSE AND DEPENDENCE).



Severe Anaphylactic and Anaphylactoid Reactions


Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including Temazepam capsules. Some patients have had additional symptoms such as dyspnea, throat closing, or nausea and vomiting that suggest anaphylaxis. Some patients have required medical therapy in the emergency department. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal.


Patients who develop angioedema after treatment with Temazepam capsules should not be rechallenged with the drug.



Precautions



General


Since the risk of the development of oversedation, dizziness, confusion, and/or ataxia increases substantially with larger doses of benzodiazepines in elderly and debilitated patients, 7.5 mg of Temazepam is recommended as the initial dosage for such patients.


Temazepam capsules should be administered with caution in severely depressed patients or those in whom there is any evidence of latent depression; it should be recognized that suicidal tendencies may be present and protective measures may be necessary.


The usual precautions should be observed in patients with impaired renal or hepatic function and in patients with chronic pulmonary insufficiency.


If Temazepam capsules are to be combined with other drugs having known hypnotic properties or CNS-depressant effects, consideration should be given to potential additive effects.


The possibility of a synergistic effect exists with the co-administration of Temazepam capsules and diphenhydramine. One case of stillbirth at term has been reported 8 hours after a pregnant patient received Temazepam capsules and diphenhydramine. A cause and effect relationship has not yet been determined (See CONTRAINDICATIONS).



Information for Patients


The text of a patient Medication Guide is printed at the end of this insert. To assure safe and effective use of Temazepam capsules, the information and instructions provided in this patient Medication Guide should be discussed with patients.



Special Concerns


“Sleep-Driving” and Other Complex Behaviors

There have been reports of people getting out of bed after taking a sedative-hypnotic and driving their cars while not fully awake, often with no memory of the event. If a patient experiences such an episode, it should be reported to his or her doctor immediately, since “sleep-driving” can be dangerous. This behavior is more likely to occur when Temazepam is taken with alcohol or other central nervous system depressants (see WARNINGS). Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with sleep-driving, patients usually do not remember these events.



Laboratory Tests


The usual precautions should be observed in patients with impaired renal or hepatic function and in patients with chronic pulmonary insufficiency. Abnormal liver function tests as well as blood dyscrasias have been reported with benzodiazepines.



Drug Interactions


The pharmacokinetic profile of Temazepam does not appear to be altered by orally administered cimetidine dosed according to labeling.



Carcinogenesis, Mutagenesis, Impairment of Fertility


Carcinogenicity studies were conducted in rats at dietary Temazepam doses up to 160 mg/kg/day for 24 months and in mice at dietary doses of 160 mg/kg/day for 18 months. No evidence of carcinogenicity was observed although hyperplastic liver nodules were observed in female mice exposed to the highest dose. The clinical significance of this finding is not known.


Fertility in male and female rats was not adversely affected by Temazepam capsules.


No mutagenicity tests have been done with Temazepam.



Pregnancy


Pregnancy Category X

(See CONTRAINDICATIONS).



Nursing Mothers


It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Temazepam capsules are administered to a nursing woman.



Pediatric Use


Safety and effectiveness in pediatric patients have not been established.



Geriatric Use


Clinical studies of Temazepam capsules did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy commonly observed in this population. Temazepam capsules 7.5 mg is recommended as the initial dosage for patients aged 65 and over since the risk of the development of oversedation, dizziness, confusion, ataxia and/or falls increases substantially with larger doses of benzodiazepines in elderly and debilitated patients.




Adverse Reactions


During controlled clinical studies in which 1076 patients received Temazepam capsules at bedtime, the drug was well tolerated. Side effects were usually mild and transient. Adverse reactions occurring in 1% or more of patients are presented in the following table:
































































Temazepam


Capsules


% incidence


(n=1076)

Placebo


% incidence


(n=783)
Drowsiness9.15.6
Headache8.59.1
Fatigue4.84.7
Nervousness4.68.2
Lethargy4.53.4
Dizziness4.53.3
Nausea3.13.8
Hangover2.51.1
Anxiety2.01.5
Depression1.71.8
Dry Mouth1.72.2
Diarrhea1.71.1
Abdominal Discomfort1.51.9
Euphoria1.50.4
Weakness1.40.9
Confusion1.30.5
Blurred Vision1.31.3
Nightmares1.21.7
Vertigo1.20.8

The following adverse events have been reported less frequently (0.5% to 0.9%):



Central Nervous System


anorexia, ataxia, equilibrium loss, tremor, increased dreaming



Cardiovascular


dyspnea, palpitations



Gastrointestinal


vomiting




Musculoskeletal


backache



Special Senses


hyperhidrosis, burning eyes


Amnesia, hallucinations, horizontal nystagmus, and paradoxical reactions including restlessness, overstimulation and agitation were rare (less than 0.5%).



Drug Abuse and Dependence


Abuse and addiction are separate and distinct from physical dependence and tolerance. Abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. Physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug and/or administration of an antagonist. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug’s effects over time. Tolerance may occur to both the desired and undesired effects of drugs and may develop at different rates for different effects.


Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease, utilizing a multidisciplinary approach, but relapse is common.



Controlled Substance


Temazepam capsules are a controlled substance in Schedule IV.



Abuse and Dependence


Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal, and muscle cramps, vomiting, and sweating), have occurred following abrupt discontinuance of benzodiazepines. The more severe withdrawal symptoms have usually been limited to those patients who received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy at doses higher than 15 mg, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. As with any hypnotic, caution must be exercised in administering Temazepam capsules to individuals known to be addiction-prone or to those whose history suggests they may increase the dosage on their own initiative. It is desirable to limit repeated prescriptions without adequate medical supervision.




Overdosage


Manifestations of acute overdosage of Temazepam capsules can be expected to reflect the CNS effects of the drug and include somnolence, confusion, and coma, with reduced or absent reflexes, respiratory depression, and hypotension. The oral LD50 of Temazepam capsules was 1963 mg/kg in mice, 1833 mg/kg in rats, and >2400 mg/kg in rabbits.



Treatment


If the patient is conscious, vomiting should be induced mechanically or with emetics. Gastric lavage should be employed utilizing concurrently a cuffed endotracheal tube if the patient is unconscious to prevent aspiration and pulmonary complications. Maintenance of adequate pulmonary ventilation is essential. The use of pressor agents intravenously may be necessary to combat hypotension. Fluids should be administered intravenously to encourage diuresis. The value of dialysis has not been determined. If excitation occurs, barbiturates should not be used. It should be borne in mind that multiple agents may have been ingested. Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation, and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. Patients treated with flumazenil should be monitored for re-sedation, respiratory depression, and other residual benzodiazepine effects for an appropriate period after treatment. The prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose. The complete flumazenil package insert including CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS should be consulted prior to use.


Up-to-date information about the treatment of overdose can often be obtained from a certified Regional Poison Control Center. Telephone numbers of certified Regional Poison Control Centers are listed in the Physicians’ Desk Reference®1.



1


Trademark of Medical Economics Company, Inc.




Temazepam Dosage and Administration


While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. In transient insomnia, a 7.5 mg dose may be sufficient to improve sleep latency. In elderly or debilitated patients, it is recommended that therapy be initiated with 7.5 mg until individual responses are determined.



How is Temazepam Supplied


Temazepam capsules, USP for oral administration are available as:


15 mg: Green and white capsules, imprinted GG 531 and supplied as:


NDC 0781-2201-01 bottles of 100


NDC 0781-2201-05 bottles of 500


NDC 0781-2201-10 bottles of 1000


30 mg: White capsules, imprinted GG 532 and supplied as:


NDC 0781-2202-01 bottles of 100


NDC 0781-2202-05 bottles of 500


NDC 0781-2202-10 bottles of 1000



Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature). Protect from moisture.


Dispense in a tight, light-resistant container.



MEDICATION GUIDE


Temazepam Capsules, USP CIV


Read the Medication Guide that comes with Temazepam capsules before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment.


What is the most important information I should know about Temazepam capsules?


After taking Temazepam capsules, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you sleepy with Temazepam capsules. Reported activities include:


  • driving a car (“sleep-driving”)

  • making and eating food

  • talking on the phone

  • having sex

  • sleep-walking

Call your doctor right away if you find out that you have done any of the above activities after taking Temazepam capsules.


Important:


  1. Take Temazepam capsules exactly as prescribed
    • Do not take more Temazepam capsules than prescribed.

    • Take Temazepam capsules right before you get in bed, not sooner.


  2. Do not take Temazepam capsules if you:
    • drink alcohol

    • take other medicines that can make you sleepy. Talk to your doctor about all of your medicines. Your doctor will tell you if you can take Temazepam capsules with your other medicines

    • cannot get a full night’s sleep



What are Temazepam capsules?


Temazepam capsules are a sedative-hypnotic (sleep) medicine. Temazepam capsules are used in adults for the short-term (usually 7 to 10 days) treatment of a sleep problem called insomnia. Symptoms of insomnia include:


  • trouble falling asleep

  • waking up often during the night

Temazepam capsules are not for children.


Temazepam capsules are a federally controlled substance (C-IV) because it can be abused or lead to dependence. Keep Temazepam capsules in a safe place to prevent misuse and abuse. Selling or giving away Temazepam capsules may harm others, and is against the law. Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines or street drugs.


Who should not take Temazepam capsules?


Do not take Temazepam capsules if you are pregnant or planning to become pregnant. Temazepam capsules may cause birth defects or harm a fetus (unborn baby).


Temazepam capsules may not be right for you. Before starting Temazepam capsules, tell your doctor about all of your health conditions, including if you:


  • have a history of depression, mental illness, or suicidal thoughts

  • have a history of drug or alcohol abuse or addiction

  • have kidney or liver disease

  • have a lung disease or breathing problems

  • are breastfeeding

Tell your doctor about all of the medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. Medicines can interact with each other, sometimes causing serious side effects. Do not take Temazepam capsules with other medicines that can make you sleepy.


Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.


How should I take Temazepam capsules?


  • Take Temazepam capsules exactly as prescribed. Do not take more Temazepam capsules than prescribed for you.

  • Take Temazepam capsules right before you get into bed.

  • Do not take Temazepam capsules unless you are able to get a full night’s sleep before you must be active again.

  • Call your doctor if your insomnia worsens or is not better within 7 to 10 days. This may mean that there is another condition causing your sleep problems.

  • If you take too many Temazepam capsules or overdose, call your doctor or poison control center right away, or get emergency treatment.


What are the possible side effects of Temazepam capsules?


Possible serious side effects of Temazepam capsules include:


  • getting out of bed while not being fully awake and do an activity that you do not know you are doing. (See “What is the most important information I should know about Temazepam capsules?”)

  • abnormal thoughts and behavior. Symptoms include more outgoing or aggressive behavior than normal, confusion, agitation, hallucinations, worsening of depression, and suicidal thoughts.

  • memory loss

  • anxiety

  • severe allergic reactions. Symptoms include swelling of the tongue or throat, trouble breathing, and nausea and vomiting. Get emergency medical help if you get these symptoms after taking Temazepam capsules.

Call your doctor right away if you have any of the above side effects or any other side effects that worry you while using Temazepam capsules.


The most common side effects of Temazepam capsules are:


  • drowsiness

  • headache

  • tiredness

  • nervousness

  • dizziness

  • nausea

  • “hangover” feeling the day after taking Temazepam capsules

  • You may still feel drowsy the next day after taking Temazepam capsules. Do not drive or do other dangerous activities after taking Temazepam capsules until you feel fully awake.

  • You may have withdrawal symptoms if you stop taking Temazepam capsules suddenly. Withdrawal symptoms can be serious and include seizures. Mild withdrawal symptoms include a depressed mood and trouble sleeping. Talk to your doctor to check if you need to stop Temazepam capsules slowly.

These are not all the side effects of Temazepam capsules. Ask your doctor or pharmacist for more information.


How should I store Temazepam capsules?


  • Store Temazepam capsules at room temperature, 68°-77°F (20°-25°C).

  • Keep Temazepam capsules and all medicines out of reach of children.

General Information about Temazepam capsules


  • Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.

  • Do not use Temazepam capsules for a condition for which it was not prescribed.

  • Do not share Temazepam capsules with other people, even if you think they have the same symptoms that you have. It may harm them and it is against the law.

This Medication Guide summarizes the most important information about Temazepam capsules. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Temazepam capsules that is written for healthcare professionals.


What are the ingredients in Temazepam capsules?


Active ingredient: Temazepam, USP


Inactive ingredients: corn starch, hypromellose, lactose monohydrate, magnesium stearate, and sodium lauryl sulfate. The capsule shells and imprinting inks contain: gelatin, iron oxide black, shellac, propylene glycol, titanium dioxide, methylparaben, butylparaben, propylparaben, benzyl alcohol, sodium propionate and edetate calcium disodium. The 15 mg capsules also contain D&C Yellow #10 and FD&C Blue #1.


Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


This Medication Guide has been approved by the U.S. Food and Drug Administration.



08-2010M


7205


Sandoz Inc.


Princeton, NJ 08540



mg Label


NDC 0781-2201-01


Temazepam


Capsules, USP CIV


15 mg


PHARMACIST: Dispense with medication


guide provided separately.


Rx only 100 Capsules


SANDOZ





mg Label


NDC 0781-2202-01


Temazepam


Capsules, USP


30 mg


PHARMACIST: Dispense with medication


guide provided separately.


Rx only 100 Capsules


SANDOZ










Temazepam 
Temazepam  capsule










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0781-2201
Route of AdministrationORALDEA ScheduleCIV    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Temazepam (Temazepam)Temazepam15 mg








































Inactive Ingredients
Ingredient NameStrength
STARCH, CORN 
D&C YELLOW NO. 10 
FD&C BLUE NO. 1 
GELATIN 
HYPROMELLOSE 2910 (3 MPA.S) 
FERROSOFERRIC OXIDE 
LACTOSE MONOHYDRATE 
MAGNESIUM STEARATE 
PROPYLENE GLYCOL 
SHELLAC 
SODIUM LAURYL SULFATE 
TITANIUM DIOXIDE 
METHYLPARABEN 
BUTYLPARABEN 
PROPYLPARABEN 
BENZYL ALCOHOL 
SODIUM PROPIONATE 
EDETATE CALCIUM DISODIUM 


















Product Characteristics
ColorGREEN (green & white)Scoreno score
ShapeCAPSULESize16mm
FlavorImprint CodeGG531
Contains      


















Packaging
#NDCPackage DescriptionMultilevel Packaging
10781-2201-01100 CAPSULE In 1 BOTTLENone
20781-2201-05500 CAPSULE In 1 BOTTLENone
30781-2201-101000 CAPSULE In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA07142701/12/1988




Temazepam 
Temazepam  capsule










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0781-2202
Route of AdministrationORALDEA ScheduleCIV    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Temazepam (Temazepam)Temazepam30 mg




























Inactive Ingredients
Ingredient NameStrength
STARCH, CORN 
D&C YELLOW NO. 10 
FD&C BLUE NO. 1 
GELATIN 
HYPROMELLOSE 2910 (3 MPA.S) 
FERROSOFERRIC OXIDE 
LACTOSE MONOHYDRATE 
MAGNESIUM STEARATE 
PROPYLENE GLYCOL 
SHELLAC 
SODIUM LAURYL SULFATE 
TITANIUM DIOXIDE